Paradoxical oncogenesis: Are all BRAF inhibitors equal?

Pigment Cell and Melanoma Research

Volumn 26, Issue 5, 2013, Pages 611-615

  Menzies, Alexander M ^a,b   Kefford, Richard F ^a,b,c,d   Long, Georgina V ^a,b,c  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

BRAF inhibitor; Dabrafenib; Melanoma; Secondary malignancy; Squamous cell carcinoma; Vemurafenib

Indexed keywords

B RAF KINASE; DABRAFENIB; TRAMETINIB; VEMURAFENIB;

ALOPECIA; ARTHRALGIA; ARTICLE; AUTOPHOSPHORYLATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ASSESSMENT; COLON ADENOMA; COLON CANCER; DISEASE COURSE; DRUG ERUPTION; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; IC 50; LEUKEMIA; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; SKIN CARCINOMA; STOMACH POLYP; STUDY DESIGN; SURVIVAL RATE; SURVIVAL TIME; TUMOR CLASSIFICATION;

BRAF INHIBITOR; DABRAFENIB; MELANOMA; SECONDARY MALIGNANCY; SQUAMOUS CELL CARCINOMA; VEMURAFENIB;

CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INDOLES; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84882919523     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12132     Document Type: Article

References (40)

1. Amanuel, B., Grieu, F., Kular, J., Millward, M., and Iacopetta, B. (2012). Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology (Phila) 44, 357-359.
2. Andrews, M., Behren, A., Chiohn, F., Tebbutt, N., Do, H., Dobrovic, A., Mariadason, J., and Cebon, J. (2012). Colorectal cancer promoted in a melanoma patient receiving dabrafenib (GSK2118436) in combination with MEK1/2 inhibitor trametinib (GSK1120212). Pigment Cell Melanoma Res. 25, 842 (abstract).
3. Anforth, R., Blumetti, T.C., Mohd Affandi, A., and Fernandez-Penas, P. (2012a). Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J. Clin. Oncol. 30, e165-e167.
4. Anforth, R., Tembe, V., Blumetti, T., and Fernandez-Penas, P. (2012b). Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res. 25, 569-572.
5. Anforth, R.M., Blumetti, T.C., Kefford, R.F., Sharma, R., Scolyer, R.A., Kossard, S., Long, G.V., and Fernandez-Penas, P. (2012c). Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 167, 1153-1160.
6. Ascierto, P.A., Minor, D., Ribas, A. et al. (2013). A Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. in press.
7. Bollag, G., Hirth, P., Tsai, J. et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
8. Callahan, M.K., Rampal, R., Harding, J.J. et al. (2012). Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367, 2316-2321.
9. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
10. Chapman, P.B., Hauschild, A., Robert, C. et al. (2012a). Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J. Clin. Oncol. 30 (Suppl), (abstract 8502).
11. Chapman, P.B., Metz, D., Sepulveda, A. et al. (2012b). Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res. 25, (abstract 847).
12. Cheng, S., Chu, P., Hinshaw, M., Smith, K., Maize, J., and Sferruzza, A. (2011). Frequency of mutations associated with targeted therapy in malignant melanoma patients. Int. J. Clin. Oncol. 29(suppl), (abstract 549).
13. Dummer, R., Robert, C., Nyakas, M. et al. (2013). Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. J. Clin. Oncol. 31 (suppl), (abstract 9028).
14. Edlundh-Rose, E., Egyhazi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., and Lundeberg, J. (2006). NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 16, 471-478.
15. Falchook, G.S., Long, G.V., Kurzrock, R. et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
16. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
17. Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
18. Gonzalez, R., Ribas, A., Daud, A., Pavlick, A., Gajewski, T.F., Puzanov, I., Teng, M.S.L., Chan, I., Choong, N.W., and Mcarthur, G. (2012). Phase 1B study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7). Ann. Oncol. 23, ixe 19 (abstract LBA28_PR).
19. Hatzivassiliou, G., Song, K., Yen, I. et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435.
20. Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012a). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
21. Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012b). Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. Int. J. Clin. Oncol. 30 (suppl), LBA8500 (abstract).
22. Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2013). An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J. Clin. Oncol. 31 (suppl), (abstract 9013).
23. Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
24. Holderfield, M., Merritt, H., Chan, J. et al. (2013). RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 23, 594-602.
25. Houben, R., Becker, J.C., Kappel, A., Terheyden, P., Brocker, E.B., Goetz, R., and Rapp, U.R. (2004). Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 3, 6.
26. Jakob, J.A., Bassett, R.L. Jr, Ng, C.S. et al. (2012). NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
27. Kefford, R., Arkenau, H., Brown, M.P., Millward, M., Infante, J.R., Long, G.V., Ouellet, D., Curtis, M., Lebowitz, P.F., and Falchook, G.S. (2010). Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Int. J. Clin. Oncol. 28 (suppl), (abstract 8503).
28. Kefford, R., Miller, W.H., Tan, D.S.-W. et al. (2013). Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J. Clin. Oncol. 31 (Suppl), (abstract 9029).
29. Lacouture, M.E., Chapman, P.B., Ribas, A. et al. (2011). Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. Int. J. Clin. Oncol. 29 (suppl), (abstract 8520).
30. Le, K., Blomain, E.S., Rodeck, U., and Aplin, A.E. (2013). Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 26, 509-517.
31. Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
32. Long, G.V., Trefzer, U., Davies, M.A. et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
33. McArthur, G., Hauschild, A., Robert, C. et al. (2012). Efficacy of vemurafenib in BRAFV600K mutation- positive melanoma disease - results from the phase 3 clinical study BRIM3. Pigment Cell Melanoma Res. 25, (abstract 871).
34. Menzies, A.M., Haydu, L.E., Visintin, L., Carlino, M.S., Howle, J.R., Thompson, J.F., Kefford, R.F., Scolyer, R.A., and Long, G.V. (2012). Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18, 3242-3249.
35. Oberholzer, P.A., Kee, D., Dziunycz, P. et al. (2012). RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321.
36. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
37. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
38. Su, F., Viros, A., Milagre, C. et al. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215.
39. Ugurel, S., Thirumaran, R.K., Bloethner, S. et al. (2007). B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2, e236.
40. Zimmer, L., Hillen, U., Livingstone, E. et al. (2012). Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J. Clin. Oncol. 30, 2375-2383.